Phase II Trial of Neoadjuvant Erlotinib Plus Chemotherapy for Treatment of ER Negative, PgR Negative and HER-2 Negative Primary Breast Cancer.

Trial Profile

Phase II Trial of Neoadjuvant Erlotinib Plus Chemotherapy for Treatment of ER Negative, PgR Negative and HER-2 Negative Primary Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2017

At a glance

  • Drugs Erlotinib (Primary) ; Carboplatin; Docetaxel
  • Indications Breast cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Jan 2017 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.
    • 31 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top